Recent studies have evaluated the therapeutic potential of rasagiline, a monoamine oxidase B inhibitor, regarding its neuroprotective potential in Parkinson's disease (PD) and in amylotrophic lateral sclerosis (ALS). Here, MAOB is linked to Parkinson disease.